ID   WM266-4
AC   CVCL_2765
SY   WM-266-4; WM 266-4; WM-2664; WM2664; WM 2664; WM266; WM-266-mel; WM266mel; WC00097
DR   BTO; BTO:0001595
DR   CLO; CLO_0009612
DR   CLO; CLO_0009615
DR   EFO; EFO_0006774
DR   CLDB; cl4726
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1676
DR   BioSample; SAMN05292442
DR   BioSample; SAMN10988367
DR   CCLE; WM2664_SKIN
DR   Cell_Model_Passport; SIDM00979
DR   CGH-DB; 9312-4
DR   Coriell; WC00097
DR   Cosmic; 687444
DR   Cosmic; 905225
DR   Cosmic; 932718
DR   Cosmic; 972276
DR   Cosmic; 1022277
DR   Cosmic; 1054856
DR   Cosmic; 1155273
DR   Cosmic; 1238103
DR   Cosmic; 1295343
DR   Cosmic; 1303070
DR   Cosmic; 1458970
DR   Cosmic; 1459638
DR   Cosmic; 1477409
DR   Cosmic; 1507624
DR   Cosmic; 1949557
DR   Cosmic; 2163804
DR   Cosmic; 2233687
DR   Cosmic; 2651885
DR   DepMap; ACH-001239
DR   ECACC; 91061233
DR   ESTDAB; ESTDAB-076
DR   GEO; GSE17551
DR   GEO; GSM827418
DR   GEO; GSM887737
DR   GEO; GSM888832
DR   GEO; GSM1138792
DR   GEO; GSM1670578
DR   IARC_TP53; 30188
DR   KCLB; 21676
DR   LiGeA; CCLE_891
DR   LINCS_LDP; LCL-1259
DR   Lonza; 1375
DR   PharmacoDB; WM2664_1663_2019
DR   Progenetix; CVCL_2765
DR   Wikidata; Q54994222
RX   PubMed=2253310;
RX   PubMed=3020539;
RX   PubMed=3856042;
RX   PubMed=4053039;
RX   PubMed=12068308;
RX   PubMed=15467732;
RX   PubMed=15592718;
RX   PubMed=17308088;
RX   PubMed=19799798;
RX   PubMed=20215515;
RX   PubMed=21424129;
RX   PubMed=22460905;
RX   PubMed=23851445;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=28158294;
RX   PubMed=28196595;
RX   PubMed=29492214;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
WW   https://www.rockland-inc.com/Product.aspx?id=51768
WW   https://physics.cancer.gov/docs/bioresource/skin/NCI-PBCF-CRL1676_WM-266-4_SOP-508.pdf
WW   https://tcpaportal.org/mclp/
CC   Part of: BRAF genetic alteration cell panel (ATCC TCP-1032).
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Doubling time: ~30 hours (PBCF).
CC   HLA typing: A*02:01,29:02; B*13:02,44:03:01; C*06:02,16:01; DPB1*02:01:02,02:01:02; DQB1*02:01,02:01; DRB1*07:01,07:01 (PubMed=15592718).
CC   HLA typing: A*02:01,29:01; B*13:02,44:02; C*06:02,06:02; DQB1*06:04,06:04; DRB1*07:01,14:103 (PubMed=25960936).
CC   Karyotypic information: Hypertriploid karyotype.
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (PubMed=12068308; PubMed=19799798; PubMed=23851445; PubMed=29492214; ATCC; CCLE; Wistar).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.04%; Native American=0%; East Asian, North=0%; East Asian, South=0.62%; South Asian=0.32%; European, North=66.56%; European, South=32.46% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-1676; probable.
CC   Discontinued: Coriell; WC00097; probable.
CC   Discontinued: ECACC; 91061233; probable.
CC   Derived from metastatic site: Right thigh; skin.
ST   Source(s): ATCC; ESTDAB; KCLB; Wistar
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12,13
ST   D16S539: 11,12
ST   D18S51: 21
ST   D19S433: 13
ST   D21S11: 29
ST   D2S1338: 19
ST   D3S1358: 15,18
ST   D5S818: 13
ST   D7S820: 8
ST   D8S1179: 13,15
ST   FGA: 21,23
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_0040 ! WM115
OI   CVCL_L033 ! WM165-1
OI   CVCL_RN55 ! WM165-2
OI   CVCL_6795 ! WM239A
OI   CVCL_RN56 ! WM239B
OI   CVCL_RN57 ! WM266-1
OI   CVCL_RN58 ! WM266-2
OI   CVCL_RN59 ! WM266-3
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 36
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=3020539; DOI=10.1073/pnas.83.19.7197;
RA   Westermark B., Johnsson A., Paulsson Y., Betsholtz C., Heldin C.-H.,
RA   Herlyn M., Rodeck U., Koprowski H.;
RT   "Human melanoma cell lines of primary and metastatic origin express
RT   the genes encoding the chains of platelet-derived growth factor (PDGF)
RT   and produce a PDGF-like growth factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7197-7200(1986).
//
RX   PubMed=3856042; DOI=10.1093/jnci/74.2.283;
RA   Herlyn M., Balaban G., Bennicelli J.L., Guerry D. IV, Halaban R.,
RA   Herlyn D., Elder D.E., Maul G.G., Steplewski Z., Nowell P.C.,
RA   Clark W.H., Koprowski H.;
RT   "Primary melanoma cells of the vertical growth phase: similarities to
RT   metastatic cells.";
RL   J. Natl. Cancer Inst. 74:283-289(1985).
//
RX   PubMed=4053039;
RA   Herlyn M., Thurin J., Balaban G., Bennicelli J.L., Herlyn D.,
RA   Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H.,
RA   Koprowski H.;
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311;
RA   Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M.,
RA   Torrice C., Hao H., Penland S., Arbiser J.L., Scott G., Zhou T.,
RA   Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L.,
RA   Sharpless N.E.;
RT   "Lack of extracellular signal-regulated kinase mitogen-activated
RT   protein kinase signaling shows a new type of melanoma.";
RL   Cancer Res. 67:1502-1512(2007).
//
RX   PubMed=19799798; DOI=10.1186/1471-2407-9-352;
RA   Casula M., Muggiano A., Cossu A., Budroni M., Caraco C.,
RA   Ascierto P.A., Pagani E., Stanganelli I., Canzanella S., Sini M.C.,
RA   Palomba G., Palmieri G.;
RT   "Role of key-regulator genes in melanoma susceptibility and
RT   pathogenesis among patients from South Italy.";
RL   BMC Cancer 9:352.1-352.11(2009).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21424129; DOI=10.3892/or.2011.1220;
RA   Manca A., Sini M.C., Izzo F., Ascierto P.A., Tatangelo F., Botti G.,
RA   Gentilcore G., Capone M., Mozzillo N., Rozzo C., Cossu A., Tanda F.,
RA   Palmieri G.;
RT   "Induction of arginosuccinate synthetase (ASS) expression affects the
RT   antiproliferative activity of arginine deiminase (ADI) in melanoma
RT   cells.";
RL   Oncol. Rep. 25:1495-1502(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=28158294; DOI=10.1371/journal.pone.0171512;
RA   Konstantakou E.G., Velentzas A.D., Anagnostopoulos A.K., Litou Z.I.,
RA   Konstandi O.A., Giannopoulou A.F., Anastasiadou E., Voutsinas G.E.,
RA   Tsangaris G.T., Stravopodis D.J.;
RT   "Deep-proteome mapping of WM-266-4 human metastatic melanoma cells:
RT   from oncogenic addiction to druggable targets.";
RL   PLoS ONE 12:E0171512-E0171512(2017).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29492214; DOI=10.18632/oncotarget.23989;
RA   Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M.,
RA   Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.;
RT   "Genetic alterations in main candidate genes during melanoma
RT   progression.";
RL   Oncotarget 9:8531-8541(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//